Results of multivariate Cox proportional hazards model of OS
| Covariate . | Primary and secondary MF . | Overt PMF . | Pre-PMF . | Post-PV/ET MF . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Constitutional symptoms | NS | NS | NS | NS | ||||
| Leukocytes >25 × 109/L | 4.81 (2.79-8.26) | <.0001 | 4.58 (1.90-11.01) | .0007 | 18.28 (4.69-71.21) | <.0001 | ||
| Hemoglobin <10 g/dL | 2.27 (1.48-3.48) | .0002 | NS | 2.61 (1.01-6.81) | .0487 | 2.75 (1.54-4.91) | .0006 | |
| Blood blasts ≥2% | 1.80 (1.10-2.96) | .0204 | 2.52 (1.17-5.46) | .0186 | NS | 2.90 (1.56-5.42) | .0008 | |
| Platelet count <100 × 109/L | 4.79 (2.72-8.44) | <.0001 | 4.80 (2.09-11.00) | .0002 | 7.98 (2.33-27.36) | .0010 | 8.25 (3.45-19.74) | <.0001 |
| BM fibrosis grade ≥2 | NS | — | — | — | ||||
| Absence of CALR1-like | NS | NS | NS | NS | ||||
| HMRMT* | 1.86 (1.24-2.80) | .0029 | NS | 11.16 (3.53-35.28) | <.0001 | NS | ||
| ≥2 HMRMTs† | NS | NS | NS | NS | ||||
| RAS/CBLMT | 1.73 (1.10-2.71) | .0177 | 2.91 (1.54-5.50) | .0010 | NS | NS | ||
| Cytogenetics‡ | ||||||||
| Favorable | Reference | Reference | Reference | Reference | ||||
| Unfavorable | NS | 2.39 (1.08-5.28) | .0314 | NS | NS | |||
| Very high risk | 4.25 (2.27-7.98) | <.0001 | 10.82 (3.57-32.76) | <.0001 | 20.33 (4.58-90.31) | <.0001 | NS | |
| Covariate . | Primary and secondary MF . | Overt PMF . | Pre-PMF . | Post-PV/ET MF . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Constitutional symptoms | NS | NS | NS | NS | ||||
| Leukocytes >25 × 109/L | 4.81 (2.79-8.26) | <.0001 | 4.58 (1.90-11.01) | .0007 | 18.28 (4.69-71.21) | <.0001 | ||
| Hemoglobin <10 g/dL | 2.27 (1.48-3.48) | .0002 | NS | 2.61 (1.01-6.81) | .0487 | 2.75 (1.54-4.91) | .0006 | |
| Blood blasts ≥2% | 1.80 (1.10-2.96) | .0204 | 2.52 (1.17-5.46) | .0186 | NS | 2.90 (1.56-5.42) | .0008 | |
| Platelet count <100 × 109/L | 4.79 (2.72-8.44) | <.0001 | 4.80 (2.09-11.00) | .0002 | 7.98 (2.33-27.36) | .0010 | 8.25 (3.45-19.74) | <.0001 |
| BM fibrosis grade ≥2 | NS | — | — | — | ||||
| Absence of CALR1-like | NS | NS | NS | NS | ||||
| HMRMT* | 1.86 (1.24-2.80) | .0029 | NS | 11.16 (3.53-35.28) | <.0001 | NS | ||
| ≥2 HMRMTs† | NS | NS | NS | NS | ||||
| RAS/CBLMT | 1.73 (1.10-2.71) | .0177 | 2.91 (1.54-5.50) | .0010 | NS | NS | ||
| Cytogenetics‡ | ||||||||
| Favorable | Reference | Reference | Reference | Reference | ||||
| Unfavorable | NS | 2.39 (1.08-5.28) | .0314 | NS | NS | |||
| Very high risk | 4.25 (2.27-7.98) | <.0001 | 10.82 (3.57-32.76) | <.0001 | 20.33 (4.58-90.31) | <.0001 | NS | |
NS, not significant.
The HMR category is defined as the presence of a mutation in any of the following genes: ASXL1, EZH2, SRSF2, and IDH1/2.
≥2 HMRMTs indicate the presence of 2 or more mutations in the ASXL1, EZH2, SRSF2, and IDH1/2 genes (2 or more mutations in the same gene are counted as 1).
According to the revised cytogenetic risk stratification.24